Breo Ellipta

Chemical Namefluticasone furoate and vilanterol
Dosage FormPowder (oral inhalation; 100/ 200 mcg fluticasone furoate and 25 mcg vilanterol)
Drug ClassCorticosteroids
SystemRespiratory
CompanyGlaxoSmithKline
Approval Year2013

Indication

  • For the long-term, once-daily, maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
  • For the once-daily treatment of asthma in patients aged 18 years and older.
Last updated on 6/22/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Breo Ellipta (fluticasone furoate and vilanterol) Prescribing Information.2021GlaxoSmithKline Research Triangle Park, NC
Document TitleYearSource
Assessment report: Relvar Ellipta. 2018EMA
Document TitleYearSource
2020 Gold pocket guide to COPD diagnosis, management, and prevention. 2020Global Initiative for Chronic Obstructive Lung Disease